With reference to the news article in The Economic Times, on July 22, 2015 captioned ‘Aurobindo Pharma Comes Under US FDA Lens’, Aurobindo Pharma has Clarified that the said facility underwent a routine GMP inspection by USFDA and there are certain observations related to the systems and procedures. The Company is appropriately responding and this has no perceived impact on the operations and exports from the said facility.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.35 |
| Dr. Reddys Lab | 1236.85 |
| Cipla | 1232.80 |
| Zydus Lifesciences | 942.40 |
| Lupin | 2332.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: